Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 7 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 12053526

    Methods for treatment using anti-alpha4beta7 antibody

    Takeda Pharmaceutical Company Limited · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  2. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Inovio Pharmaceuticals, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  3. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  4. US 12054557

    Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  5. US 12053534

    Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  6. US 12049489

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  7. US 12037388

    Anti-IL-33 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  8. US 12037401

    Anti-TrkB monoclonal antibodies and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  9. US 12030935

    Anti-PDGF-B antibodies and pharmaceutical composition thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  10. US 12029788

    Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  11. US 12024556

    Anti-Staphylococcus antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  12. US 12024570

    Anti-CTLA-4 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 2, 2024 · Expires Jun 27, 2044

    granted
  13. US 12018087

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  14. US 12012444

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  15. US 12012445

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  16. US 12012454

    Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  17. US 12013406

    Methods of detecting anti-folic acid antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  18. US 12012460

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

    Dyne Therapeutics, Inc. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  19. US 12006364

    Anti-CD100 antibodies and methods for using the same

    VACCINEX, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  20. US 12006365

    Human anti-semaphorin 4D antibody

    VACCINEX, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  21. US 12006363

    Anti-tetraspanin 33 agents and compositions and methods for making and using the same

    BioLegend, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  22. US 11999799

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  23. US 11999777

    Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  24. US 11999796

    Anti-CD70 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 4, 2024 · Expires May 30, 2044

    granted